NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
GeoVax Labs, Inc. GOVX
19 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 2.5M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 2.5 · Net income -21.5
Compound annual growth
Revenue compounded at +6.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−862 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -869.3% · Net -862.3%
ROE
FY2025 · ROE -483.8%
Each USD of equity lost 484 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | · | −0.0 | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | · | · |
| EPS, diluted $ | · | · | · | · | −3.04 | −2.14 | −781.87 | −15610.33 | −0.03 | −0.08 | −0.08 | −0.10 | −0.11 | −0.12 | −0.15 | −0.18 | −0.22 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −483.8 | −462.3 | −160.5 | −90.6 | −266.6 | −74.0 | · | · | · | −452.8 | −228.8 | −148.8 | −124.2 | −230.3 | −184.8 | −98.5 | −101.8 | −139.2 | −160.2 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.11 | 0.06 | 0.03 | 0.03 | 0.00 | 0.00 | 0.02 | 0.02 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 8 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007